GREAT PLACE TO WORK Best Companies to Work for 2014 India

Claris

Claris receives Prior Approval Supplement for Furosemide Injection in US

Ahmedabad, India, August 12th, 2015: Claris Lifesciences Limited (Claris) announced today that it has received the Prior Approval Supplement (PAS) for Furosemide Injection in the United States of America (US). The Company had received the original approval for this ANDA in January 2014 and was selling the products in the US in 2014. But, Since January 2015, the company has been facing supply issues from its raw material supplier and has not been able to supply its product to the US. The Company had filed a PAS application to append an additional supplier to the ANDA, this process was done for redundancy and to ensure a consistent supply of the API for its finished formulation sold in the US. With this approval, alterative vendor has been appended to the ANDA this will allow the company to recommence its supplies to the US.

The product had been facing supply issues in USA during the past year on various occasions and has also featured in the USFDA shortage list since June 2012.

Claris is also one of the few injectables companies in India to have its own front end in the US, the company markets its products through its wholly owned subsidiary Claris Lifesciences Inc. The Company has 13 ANDAs approved in its name across 8 molecules. The Company has a under registration pipeline of 24 ANDAs across 21 molecules having an estimated addressable market size of USD 2.2 billion

###

Disclaimer

This press release may include "forward-looking statements" which involve a number of risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future. Claris Lifesciences Limited does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof. Market information mentioned in the press release is based on IMS Data (June 2013) and/or internal estimates of the company.

About Claris Lifesciences Limited

Claris Lifesciences Limited (BSE Code: 533288) is the holding company with three segmental revenues (i) the Speciality Injectables Business which is housed in a wholly owned subsidiary; Claris Injectables Limited, (ii) 20% stake in the Joint Venture with Otsuka and Mitsui for the Infusion Business in India and Emerging Markets, and (iii) the Treasury and Cash management for the funds in the HoldCo.

For more information about the company, log on to: www.clarislifesciences.com

CLARIS LIFESCIENCES LIMITED INDIA AHMEDABAD

Claris Lifesciences Limited
Claris Corporate Headquarters, Nr. Parimal Rly. Crossing,
Ellisbridge, Ahmedabad 380 006, India.
Tel: +91-79-26563331, 66309339 Fax: +91-79-26408053
www.clarislifesciences.com
(Corporate Identity Number: L85110GJ1994PLC022543)

GREAT PLACE TO WORK Best Companies to Work for 2014 India

Claris

About Claris Lifesciences Inc.

Claris Lifesciences Inc. is a pure play injectables company, involved in marketing and distribution of generic injectables in United States. The company is a wholly-owned subsidiary of Claris Lifesciences Ltd. Headquartered in New Jersey, USA, Claris Inc. has full-fledged presence to cater to the growing and unmet demands of hospitals and medical professionals for injectable products. Clairs Inc. has full-fledged sales, marketing and regulatory capabilities established to ensure seamless product availability and after-sales services and to ensure customer delight at every step of value chain.

With 8 molecules across 13 ANDAs and a growing portfolio, Claris Inc. is one of a few players to have launched technologically-advanced and complex-to-manufacture products in premix bags both PVC and non-PVC materials. The other technological platforms include glass vials and ampoules. Having established a strong team to address customer needs personally and provide prompt & satisfactory services, the company places major emphasis on quality and technology of products, which are manufactured at cGMP compliant facilities inspected by FDA.

For more information about the company, log on to: http://www.us.clarislifesciences.com

CLARIS LIFESCIENCES LIMITED INDIA AHMEDABAD

Claris Lifesciences Limited
Claris Corporate Headquarters, Nr. Parimal Rly. Crossing,
Ellisbridge, Ahmedabad 380 006, India.
Tel: +91-79-26563331, 66309339 Fax: +91-79-26408053
www.clarislifesciences.com
(Corporate Identity Number: L85110GJ1994PLC022543)